{"slug":"education-audit","tag":"education-audit","variants":["education-audit"],"description":"No description yet","count":12,"kinds":{"term":3,"trial":4,"paper":5},"related":[{"slug":"local-treatment","tag":"local-treatment","shared":9},{"slug":"classification","tag":"classification","shared":1},{"slug":"randomised-phase-2","tag":"randomised-phase-2","shared":1},{"slug":"subtyping-strategy","tag":"subtyping-strategy","shared":1}],"records":[{"id":"tnbc-molecular-subtyping","kind":"term","name":"TNBC molecular subtyping","route":"/terms/tnbc-molecular-subtyping/","tldr":"TNBC RNA subtyping compares gene-expression patterns under a named research classifier. Tissue mixture, method and version matter, and the result is separate from receptor tests or a treatment choice."},{"id":"completion-surgery","kind":"term","name":"Completion surgery","route":"/terms/completion-surgery/","tldr":"Completion surgery is a further operation after an earlier procedure and its findings. The tissue, reason and clinical setting determine the question; a pathology finding does not select one operation automatically."},{"id":"regional-nodal-irradiation","kind":"term","name":"Regional nodal irradiation in breast cancer","route":"/terms/regional-nodal-irradiation/","tldr":"Regional nodal irradiation treats selected lymph-node regions. The exact fields, pretreatment findings and response after earlier therapy determine the clinical question."},{"id":"curb-oligoprogression","kind":"trial","name":"CURB: SBRT for oligoprogressive breast or non-small-cell lung cancer","route":"/trials/curb-oligoprogression/","status":"mixed","tldr":"CURB tested added SBRT for limited progression during systemic treatment. Its lung and breast subgroup findings should not be combined into one rule for every metastatic cancer."},{"id":"nrg-br002","kind":"trial","name":"NRG-BR002: metastasis-directed ablation in limited metastatic breast cancer","route":"/trials/nrg-br002/","status":"negative","tldr":"NRG-BR002 did not meet its progression endpoint for added metastasis-directed ablation in a selected breast-cancer population. The planned phase 3 portion did not proceed."},{"id":"alliance-a011202","kind":"trial","name":"Alliance A011202: axillary treatment after residual positive sentinel nodes","route":"/trials/alliance-a011202/","status":"active","tldr":"A011202 studies how to treat the axilla when sentinel nodes remain positive after chemotherapy. Both registry arms include radiation; this differs from the B-51 ypN0 question."},{"id":"future-super","kind":"trial","name":"FUTURE-SUPER","route":"/trials/future-super/","status":"positive","tldr":"FUTURE-SUPER tested a defined subtype-linked treatment strategy in advanced TNBC. The pooled phase 2 PFS comparison was positive; the current registry does not establish availability."},{"id":"paper-booster-ablation-immunotherapy-2025","kind":"paper","name":"BOOSTER: ablation during continuing immunotherapy for limited residual lung cancer","route":"/key-papers/paper-booster-ablation-immunotherapy-2025/","tldr":"This small randomised phase 2 trial found longer progression-free survival with ablation in selected lung cancer after an immunotherapy response. It did not test SBRT or establish one ablation method as universally best."},{"id":"paper-curb-oligoprogression-lancet-2024","kind":"paper","name":"CURB: adding SBRT for oligoprogressive breast or non-small-cell lung cancer","route":"/key-papers/paper-curb-oligoprogression-lancet-2024/","tldr":"CURB found longer progression-free survival overall with added SBRT, with different findings in its lung and breast cohorts. The small breast comparison did not show a statistically significant improvement."},{"id":"paper-nrg-br002-jco-2026","kind":"paper","name":"NRG-BR002: metastasis-directed ablation during first-line therapy for limited metastatic breast cancer","route":"/key-papers/paper-nrg-br002-jco-2026/","tldr":"NRG-BR002 did not show improved progression-free or overall survival from adding metastasis-directed ablation in its selected breast-cancer population. This result is distinct from local palliation."},{"id":"paper-nsabp-b51-nejm-2025","kind":"paper","name":"B-51: regional radiation after node-positive breast cancer becomes ypN0","route":"/key-papers/paper-nsabp-b51-nejm-2025/","tldr":"B-51 did not show a statistically significant recurrence benefit from regional irradiation in its selected post-chemotherapy ypN0 population. The confidence interval and surgery-specific comparison remain important."},{"id":"paper-future-super-lancet-oncology-2024","kind":"paper","name":"FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC","route":"/key-papers/paper-future-super-lancet-oncology-2024/","tldr":"This randomised phase 2 trial found longer progression-free survival with a specified subtype-based combination strategy than with nab-paclitaxel alone, with more serious treatment-related adverse events."}]}